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Abstract 
We have screened sporadic early-onset Alzheimer’s disease (sEOAD, n=408) samples using the 
NeuroX array for known causative and predicted pathogenic variants in 16 genes linked to familial 
forms of neurodegeneration. We found two sEOAD individuals harbouring a known causative variant 
in PARK2 known to cause early-onset Parkinson’s disease (EOPD); p.T240M (n=1) and p.Q34fs delAG 
(n=1). Additionally, we identified three sEOAD individuals harbouring a predicted pathogenic variant 
in MAPT (p.A469T) which has previously been associated with AD. It is currently unknown if these 
variants affect susceptibility to sEOAD, further studies would be needed to establish this. This work 
highlights the need to screen sEOAD individuals for variants that are more classically attributed to 
other forms of neurodegeneration. 
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1. Introduction 
Alzheimer’s disease (AD) is the commonest form of dementia in the world. AD and other dementias 
were the fourth leading cause of death in high-income countries in 2012 (WHO, 2012). Sporadic 
early-onset Alzheimer’s disease (sEOAD) has a disease onset ≤ 65 years of age and these individuals 
do not harbour a known causative mutation, the remaining sporadic cases are classified as late-
onset Alzheimer’s disease (LOAD). Both forms of AD have a complex aetiology with heritability 
estimated to be 92-100% for sEOAD (Wingo, et al., 2012) and 70% for LOAD (Gatz, et al., 2006). 
Given the difference in heritability and age of onset between sEOAD and LOAD, it is likely that 
sEOAD patients have a more penetrant genetic aetiology and thus provide a good cohort to explore 
the genetics of AD.  
Many types of dementia have a neuropathology and/or clinical crossover, for example Parkinson’s 
disease with/without dementia (PDD/PD) have alpha-synuclein deposits in the brain and a similar 
clinical presentation to dementia with Lewy bodies (DLB) (Jellinger, 2014). Mixed dementia has 
features linked to more than one type of dementia, such as AD with cerebrovascular lesions and/or 
Lewy bodies (Jellinger, 2014). It is not surprising then that some genetic loci identified thus far are 
associated with multiple types of dementias; the commonest example is that of APOE ε4 which is 
associated with AD (Corder, et al., 1993), posterior cortical atrophy (PCA) (Carrasquillo, et al., 2014) 
and DLB (Bras, et al., 2014). It is believed that sporadic AD could be in part due to the aggregate of 
multiple causative variants, therefore it is easy to imagine that different types of dementia have 
overlapping genetics; whereby a portion of variants that contribute to one dementia are also seen to 
contribute to a different type of dementia. Alternatively different types of dementia could be a 
result of pleiotropy, for example it has recently been reported that the alpha-synuclein gene (SNCA) 
is associated with DLB but this is a different haplotype to that associated with PDD (Bras, et al., 
2014). 
3 
 
The NeuroX is a customised Illumina HumanExome DNA microarray; the first version of the chip 
contains 267,607 markers, most of which genotype rare missense variants, notably most of the 
genes in the human genome have at least one variant genotyped. The NeuroX includes standard 
content (242,901) designed by Illumina together with custom content (24,706) designed to be 
‘neuro-specific’. The custom content was selected to genotype specific variants and genes linked to 
neurologic diseases, the inclusion criterion was determined using literature searches and genotyping 
data available before 2014. A more descriptive explanation of the NeuroX can be found in the 
consortia’s published paper (Nalls, et al., 2015). The NeuroX provides a convenient approach to 
screen for causative mutations and test for genetic crossover and/or pleiotropy amongst neurologic 
diseases. 
We report the screening of 408 sEOAD individuals with the aim to identify causative or predicted 
pathogenic variants in 16 selected genes using the NeuroX. These 16 genes are linked to familial 
forms of neurodegeneration including Alzheimer’s disease (APP, PSEN1 and PSEN2), frontotemporal 
dementia/amyotrophic lateral sclerosis (C9orf72, CHMP2B, FUS, GRN, MAPT, TARDBP and VCP), 
Parkinson’s disease (LRRK2, PARK2, PARK7, PINK1 and SNCA) and prion disease (PRNP); all have 
pathogenic variants highlighted in freely accessible online databases. 
  
4 
 
2. Materials and Methods 
Methods were conducted according to the manufacturer’s instructions unless otherwise stated. All 
sporadic early-onset Alzheimer’s disease (sEOAD) samples were screened for known causative 
variants in APP exons 16 and 17 by Sanger sequencing and in PSEN1/PSEN2 using the NeuroX data, 
individuals harbouring a causative variant in either of these genes were removed prior to this 
analysis (Barber, et al., 2016). 
2.1. Samples 
sEOAD individuals (n=408) had an age of disease onset ≤ 65 years of age (Table 1).  For 28 individuals 
where AAO was not documented, it was derived assuming 8 years disease duration from age at 
death (Ryman, et al., 2014). 
5 
 
 
  N Mean AAO (±SD) Females (%) APOE ε4+ (%) APOE ε4 MAF APOE ε4ε4 (%) Definite Probable 
Bristol 21 53.3 (5.3) 9 (42.9) 10 (47.6) 0.31 3 (14.3) 21 0 
Manchester 328 57.1 (5.5) 156 (47.6) 196 (59.8) 0.58 46 (14.0) 53 275 
Nottingham 26 58.2 (6.3) 12 (46.2) 11 (42.3) 0.23 1 (3.8) 5 21 
Oxford 33 55.6 (4.2) 19 (57.6) 19 (57.6) 0.33 3 (9.1) 24 9 
All 408 56.8 (5.5) 196 (48.0) 236 (57.8) 0.53 53 (13.0) 103 305 
 
Table 1 
Demographics of sporadic early-onset Alzheimer’s disease (sEOAD) cohort 
The cohort contains individuals from multiple centres; each centre is represented one per row. The number of individuals (N) from each centre is given 
along with the mean age of onset with standard deviation (Mean AAO (±SD)), this is followed by the number and percentage of female individuals per 
centre (Females (%)), the number and percentage of individuals harbouring at least one APOE ɛ4 allele (APOE ε4+ (%)), APOE ε4 minor allele frequency 
(APOE ε4 MAF) and number and percentage of individuals with APOE ε4ε4 genotype (APOE ε4ε4). The final columns state the number of individuals classed 
as either post mortem verified (Definite) or probable (Probable) Alzheimer’s disease according to NINCDS-ADRDA and CERAD guidelines. Key: N, number of 
individuals; SD, standard deviation. 
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sEOAD individuals were diagnosed as either definite or probable Alzheimer’s disease (AD) according 
to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
disease and Related Disorders Association (NINCDS-ADRDA), and the Consortium to Establish a 
Registry for Alzheimer’s disease (CERAD) guidelines. All samples used in this study were received 
with informed consent and experimental procedures were approved by the local ethics committee, 
Nottingham Research Ethics Committee 2 (REC reference 04/Q2404/130). All experimental 
procedures were conducted in accordance with approved guidelines. 
DNA was extracted from blood or brain tissue using a standard phenol chloroform extraction 
method. DNA quality and quantity was assessed by gel electrophoresis and NanoDrop™ 3300 
spectrometry respectively. 
2.2. Quality control of NeuroX data 
Quality control (QC) of the NeuroX intensity data was conducted in Genome Studio version 2011.1 
using the genotyping module version 1.9.4 with ‘exclude female Y-SNPs from SNP Statistics’ checked 
to ensure variants on the Y chromosome aren’t incorrectly labelled as having a low call rate. 
Standard content was clustered using the CHARGE cluster file version 1.0 (Grove, et al., 2013). All 
quality control of the markers in Genome Studio were conducted using only the best quality samples 
(≥ 99% call rate).  Standard content with call rate < 100% and all custom content were clustered 
using Genome Studio’s clustering algorithm, this was followed by manual assessment and clustering 
for all non-autosomal markers, and manual assessment and clustering of autosomal markers 
matching any of the following criteria: ≤ 99% call rate, excess heterozygote calls, excess 
heterozygote calls relative to expected HWE, deficient heterozygote calls relative to expected HWE, 
low intensity, unexpected cluster positions, wide clusters or low cluster separation (Grove, et al., 
2013). Once quality control had been conducted in Genome Studio the genotyping calls were 
exported from Genome Studio to PLINK format in the forward orientation with all samples and all 
variants included. The MapInfo (location) was updated for 29 markers that originally had no location 
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(Supplementary Table 1), and the chromosome was updated for 121 markers from chromosome X 
to the pseudo autosomal region (Supplementary Table 2). Additional quality control was performed 
in PLINK v1.07. Samples were first removed if they had a call rate < 98% followed by markers that 
had a call rate < 95%. Further samples were removed if they failed the following criteria: samples 
with identity by decent > 18.75% or heterozygosity rate outside ± 3 SD of the mean, both 
determined using an LD pruned version of the dataset (indep-pairwise 50 5 0.2) with only common 
autosomal variants (MAF > 0.1). Further common markers were removed if they had significant 
deviation (p.value < 1.2E-6) from Hardy-Weinberg equilibrium in control samples (data not shown). 
The final NeuroX dataset had 265,049 markers with an average sample call rate of 99.9%.  
2.3. Samples harbouring a known causative variant 
A total of 1196 variations are documented in the PD online mutation database (PDMDB) 
[http://www.molgen.vib-ua.be/PDMutDB/ accessed August 2013], AD&FTD online mutation 
database (AD&FTDMDB) [http://www.molgen.vib-ua.be/ADMutations/ accessed August 2013] 
(Cruts, et al., 2012) and Human Prion Mutation Database [http://www.mad-
cow.org/prion_point_mutations.html accessed November 2014] combined. These databases 
document variants across 16 genes known to cause familial forms of neurodegeneration (APP, 
C9orf72, CHMP2B, FUS, GRN, LRRK2, MAPT, PARK2, PARK7, PINK1, PRNP, PSEN1, PSEN2, SNCA, 
TARDBP and VCP), and includes three genes that are linked to Alzheimer’s disease (APP, PSEN1 and 
PSEN2). The databases include variants that don’t cause disease (not pathogenic), have unknown 
pathogenicity (pathogenic nature unclear) and are known to cause disease (known causative) 
(Supplementary Table 3). 1075 of these database variants are SNPs, small insertions or small 
deletions and therefore had the potential to be genotyped on the NeuroX. 
The genomic position (relative to the reference build GRCh37, 27 Feb 2009), reference allele and 
alternative allele were successfully calculated for 265,828 markers (99%) on the NeuroX using an in-
house script. A second in-house script was used to establish if any of these markers genotyped the 
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1075 database variants. It was established that 412 (38%) of these variants were genotyped on the 
NeuroX and included 38% of AD related variants, 32% of FTD/ALS related variants, 47% of PD related 
variants and 12% of prion related variants. Of the 412 variants, 407 passed quality control 
procedures and inspection of the cluster plots found they all clustered well. 
The 407 database variants were filtered to retain only those labelled as causative and were also 
polymorphic in our sEOAD cohort, four variants fit this criterion. The sEOAD samples harbouring 
these four variants were identified and their genotype verified with Sanger sequencing. As expected 
these four variants were not located in APP, PSEN1 or PSEN2 as our sporadic cohort had been 
previously filtered to remove individuals harbouring these variants. 
2.4. Samples harbouring a predicted pathogenic variant 
It was established that 662 variants were genotyped on the NeuroX which passed QC and were 
located in one of the 16 genes linked to neurodegenerative diseases (Table 2), this list excluded the 
407 known causative variants analysed previously. The gene ID, European minor allele frequency 
(MAF) from the 1000 Genomes Project (Genomes Project, et al., 2012), Polyphen score and SIFT 
score were retrieved for all 662 variants using ENSEMBL’s variant effect predictor (VEP) (McLaren, et 
al., 2010) which was installed locally and run over the command line using reference genome build 
GRCh37, Polyphen HDIV database  and predicting one consequence per variant.  
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Variants were filtered to retain only those that were polymorphic in our sEOAD cohort, had a 1000 
Genomes European MAF < 0.01, and were predicted to be probably pathogenic; which is defined 
here as a ‘deleterious effect’ by SIFT (≤0.05) or ‘probably damaging’ by PolyPhen (≥0.909). Three 
variants fit this criterion. The sEOAD samples harbouring these three variants were identified and 
their genotype verified with Sanger sequencing. 
2.5. Sanger sequencing 
Genomic DNA was amplified in a final volume of 15 μl using the following constituents and final 
concentrations: 2 ng/μl gDNA, 1 pM forward primer, and 1 pM reverse primer, 1x Buffer (BioLabs), 
0.2 mM dNTPs (Thermo Scientific), 0.1 U/μl LongAmp Taq DNA polymerase (New England Biolabs) 
and molecular grade water to the required volume. The reaction was subjected to the following 
thermal conditions: initial denaturation step of 94°C for 2 min, followed by 35 cycles of 94°C for 30 
sec, 57°C for 15 sec and 72°C for 45 sec, finished with a final extension step at 72°C for 7 min. A 
reaction containing no gDNA was included as a negative control. The PCR products were cleaned 
using ExoSAP-IT (Affymetrix). Primers used for sequencing were the same as those used for 
amplification (Eurogenomics). The primers used for p.T240M were forward 
5’GCTCGTGTGGCAGAACAATA 3’ and reverse 5’ACACCCCACCTCTGACAAG 3’; the product was 202 bp 
(base pairs) long. The primers used for p.G255V were forward 5’ TGGCAATCAAGACCAGAGTG 3’ and 
reverse 5’ GATTCATGCAATCCTCCACA 3’; the product was 243 bp long. The primers used for p.Q34fs 
were forward 5’ TCAGGCATGAATGTCAGATTG 3’ and reverse 5’ CCTTCCAATTTCCTTGGTCA 3’; the 
product was 272 bp long. The primers used for p.G107V were forward 5’AGAGCTGAGGCACCTTGGTA 
3’ and reverse 5’ ATGGCAGGCAATTCCAGTT 3’; the product was 235 bp long. The primers used for 
p.S427F were forward 5’ TCCACACGTTCCTCTGCTAA 3’ and reverse 5’ AGCAGCCTGGTTCTTTTCAA 3’; 
the product was 230 bp long. The primers used for p.A469T were forward 5’ 
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GGCTGGTGTTGACTCTTGGT 3’ and reverse 5’ TCTTACCAGAGCTGGGTGGT 3’; the product was 206 bp 
long. 
Amplicons were sequenced using the Sanger di-deoxy method in the forward and reverse directions. 
Cleaned PCR products were sequenced in a final volume of 10 μl using 4 μl PCR product and the 
following constituents: 0.5 pM forward/reverse primer, 1x BigDye Sequencing Buffer (Life 
Technologies), 0.25x BigDye Terminator v3.1 (Life Technologies) and molecular grade water to the 
required volume. The reaction was subjected to the following thermal conditions: 25 cycles of 96°C 
for 30 sec, 50°C for 15 sec and finally 60°C for 4 min. The reactions were cleaned using Performa DTR 
Gel filtration Cartridges (Edge Biosystems). The eluent was dried and sequencing was performed on 
an ABI 3130 automated sequencer. 
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3. Results 
sEOAD samples (n=408) were genotyped on the NeuroX DNA microarray. These samples were 
screened for variants known to cause disease (known causative variants) of 13 genes linked to 
familial forms of neurodegeneration (non-AD familial genes) and variants predicted to be pathogenic 
(predicted pathogenic variants) in 16 genes linked to familial forms of neurodegeneration (familial 
genes). 
3.1. Validated genotypes 
The NeuroX identified three sEOAD samples harbouring a known causative variant in two of the 13 
non-AD familial genes and ten sEOAD samples harbouring a predicted pathogenic variant in one of 
the 16 familial genes. All samples were clinically diagnosed as having probable AD. Sanger 
sequencing confirmed that nine samples harboured a variant. Figure 1 shows the sequence 
chromatograms for the thirteen samples and Table 2 lists their genotypes. 
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A Marker Genomic 
Position 
Variant 
 
Base  
Change 
MAF Protein 
Change 
Gene Disease Sample Seq Gender AAO APOE ε 
 exm593516 6:162394349 rs137853054 aCg/aTg 2.8e-04 p.T240M PARK2 PD (R) M177 (Het) C Female 52 44 
 NeuroX_PARK2_Gln34fs_del_AG 6:162864411-2 rs55777503 cga.cAG.ggg/cga.cgg.ggt 2.9e-04 p.Q34fs PARK2 PD (R) M099 (Het) C Female 56 44 
 NeuroX_PARK2_Gln34fs_del_A 6:162864412 rs748142049 cga.cAg.ggg/cga.cgg.ggg 8.2e-06 p.Q34fs PARK2 PD (R) M099 (Het) U Female 56 44 
 NeuroX_16:31196410 16:31196410 - gGc/gTc U/K p.G225V FUS ALS (R) M215 (Het) U Female 53 34 
              
B Marker Genomic 
Position 
rsID Base Change  Protein 
Change 
Gene Disease Individual  Seq Gender AAO APOE ε 
 exm1330962 17:44055753 rs144397565 gGc/gTc 2.4e-05 p.G107V MAPT FTD (D) M820 (Het) C Male 65 34 
 exm1331018 17:44067341 rs143956882 tCc/tTc 0.001 p.S427F MAPT FTD (D) M357 (Het) C Male 53 33 
         M143 (Het) C Female 57 34 
         M697 (Het) U Female 48 24 
         M245 (Het) C Female 63 44 
 exm1331027 17:44068850 rs143624519 Gcc/Acc 0.001 p.A469T MAPT FTD (D) M168 (Het) C Female 58 33 
         M172 (Het) U Female 58 34 
         M382 (Het) U Female 52 33 
         M691 (Het) C Male 55 34 
         M699 (Het) C Male 58 33 
 
Table 2 
Samples harbouring a variant in a familial gene 
Samples identified by the NeuroX as harbouring a known causative variant in one of the 13 none AD familial genes (A) or a predicted pathogenic variant in one of the 16 familial 
genes. The name of the NeuroX marker (Marker) is followed by information about the variant genotyped by the marker, including the genomic position of the variant in reference 
genome build GRCh37 and format chromosome:base position (Genomic Position), and the reference ID of the variant according to dbSNP (Variant). The variant is given at nucleotide 
level (Base Change) on the sense strand, the minor allele frequency in the general population according to ExAC (MAF) and amino acid level (Protein Change). Also listed is the gene 
the variant resides in (Gene) and the disease most associated with the gene, the Mendelian pattern of inheritance is given in brackets (Disease). The sample(s) harbouring the variant 
(Sample) is followed by the results of Sanger sequencing (Seq) and patient information including gender (Gender), age at onset (AAO) and APOE ε status (APOE ε). Key: rsID, reference 
single nucleotide polymorphism identification; U/K, unknown; FTD, frontotemporal dementia; D, dominant; R, recessive; C, Sanger sequencing confirmed the genotype of this 
sample; U, Sanger sequencing did not confirm the genotype of this sample.  
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Sanger sequencing confirmed that eight samples harboured the minor allele indicated by the NeuroX 
and one sample (M820) harboured an alternative minor allele. M820 appeared heterozygous for 
G>A base change (rs144397565, p.G170D), however sequencing confirmed it was heterozygous for 
G>T base change (rs144397565, p.G170V). Evidently this position is trimorphic, as this marker uses 
the Infinium II probe design it was able to detect both minor alleles but was unable to differentiate 
between them.  
3.2. Invalidated genotypes 
Of the variants not confirmed by Sanger sequencing, one sample (M099) was identified as 
heterozygous for p.Q34fs (delA) in addition to the confirmed variant p.Q34fs (delAG) at the same 
position. Notably the probe sequence for both markers was identical. As both deletions are followed 
by the same nucleotide (G), the single nucleotide extension design meant this probe was capable of 
detecting both variants, in this instance both probes detected the delAG variant. 
Four samples (M215, M697, M172, M382) failed to verify with initial Sanger sequencing; the cluster 
plots were examined to establish call quality, which were found to be good (Figure 2). Three of the 
four samples (M215, M697 and M382) were re-sequenced from the original DNA stock; all three 
gave the same result as originally obtained (unconfirmed), thereby obviating a sample ‘mix-up’. We 
were unable to re-sequence M172 as no additional DNA was available. It is interesting to note that 
variant p.G225V is located within a GGC repeat region and this could be the reason for the 
discrepancy between the NeuroX genotype and sequencing result. Alternatively, the NeuroX 
genotypes could be correct for these samples and the PCR reaction may have resulted in allele 
dropout (Blais, et al., 2015), however it would be advisable to use a different primer pair as this 
might permit detection of the other allele. 
In addition to the above, twenty-five samples were identified as harbouring the variant p.Q130fs 
(rs63750768, gaT.AGT/ga) in the GRN gene. Similar to the situation with M820 (as described in 
Section 3.1), Ghani and colleagues confirmed that this marker also genotypes a common alternative 
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minor allele at the same position (rs25646, gaT/gaC) (Ghani, et al., 2015). Consequently, this variant 
was discarded from further investigation. 
4. Discussion 
4.1. Known causative variants 
Two sEOAD samples were confirmed heterozygous for a known causative variants; p.T240M (n=1) 
and p.Q34fs (delAG, n=1). Both of these variants are located in the gene PARK2. Known causative 
variants in PARK2 include point mutations and exon rearrangements/deletions/duplications, often 
as homozygote or compound heterozygotes in early-onset PD (EOPD).  
Variant p.T240M has been seen in EOPD as a compound heterozygote with various exon deletions or 
duplications (Amboni, et al., 2009,Deng, et al., 2006,Periquet, et al., 2003,Sironi, et al., 2008), it has 
also been seen as a homozygote (Madegowda, et al., 2005) and a heterozygote (Camargos, et al., 
2009). A compound heterozygote with an exon deletion has also been seen in one healthy individual 
(Deng, et al., 2006). Variant p.Q34fs (delAG) has been seen in EOPD as a compound heterozygote 
with exon deletions or SNPs (Abbas, et al., 1999,Guo, et al., 2008,Guo, et al., 2010,Hedrich, et al., 
2002,Illarioshkin, et al., 2003,Koziorowski, et al., 2010,Lesage, et al., 2008,Lohmann, et al., 
2009,Scherfler, et al., 2004), it has also been seen as a homozygote (Koziorowski, et al., 
2010,Scherfler, et al., 2004) and a heterozygote (Brooks, et al., 2009,Bruggemann, et al., 2009). A 
compound heterozygote with an exon deletion has also been seen in LOPD (Lesage, et al., 2008). 
Previous findings would suggest that p.T240M and p.Q34fs (delAG) elicit risk for PD, in particular 
EOPD. Finding these variants in our sEOAD cohort would suggest that they could also elicit risk to 
sEOAD; however we only found each of them in one sample (0.25% of our sEOAD cohort) as a 
heterozygote and we don’t know if these individuals were compound heterozygotes. These variants 
could elicit risk to sEOAD, however a large case-control association study would be needed to 
establish this. 
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Both of these patients (M117 and M099) had an APOE ε4ε4 status and there was nothing unusual 
about their presentation or progress, which suggests that a misdiagnosis is unlikely. However, M099 
had a mother who was said to have had motor neuron disease (MND), so there was likely to have 
been physical signs in her, possibly consistent with a known causative variant in PARK2.  
4.2. Predicted pathogenic variants 
Seven sEOAD samples were confirmed heterozygous for a predicted pathogenic variant; p.G107V 
(n=1), p.S427F (n=3) or p.A469T (n=2). All these variants are located in the gene MAPT and are 
named in reference to the longest tau transcript (tau-g). The majority of known causative variants in 
MAPT are SNPs with autosomal dominant inheritance and result in FTD. 
Variant p.G107V was predicted to be probably damaging (1.00) by Polyphen and deleterious (0) by 
SIFT, it is located in exon 4 of MAPT where no known causative variants have been documented. 
Variant p.S427F was predicted to be deleterious (0.02) by SIFT and probably damaging (0.99) by 
Polyphen, it is located in exon 4a which is spliced out in the transcript htau40 and thus not present 
in the human brain (Liu and Gong, 2008,Pittman, et al., 2006). It is unlikely this variant has a 
functional effect in the brain if the transcripts containing this variant are not present.  
Variant p.A469T is also called p.A152T in htau40. It was predicted to be deleterious (0.05) by SIFT 
and benign (0.30) by Polyphen. This variant significantly increases the risk for both FTD 
(p.value=0.0005, OR=3.0 (CI: 1.6–5.6)) and AD (p.value=0.004, OR=2.3 (CI: 1.3–4.2)) when compared 
to controls (Coppola, et al., 2012).  In vitro site-directed mutagenesis of human tau cDNA showed the 
variant resulted in less efficient binding to microtubules and a pronounced increase in the formation 
of tau oligomers (Coppola, et al., 2012). Furthermore, Isogenic human iPSCs generated from 
fibroblasts saw the variant result in axonal degeneration and cell death (Fong, et al., 2013).  Whether 
heterozygous p.A469T in humans would cause the same effect is unknown. Notably, this variant is 
located in exon 7, the downstream residue (p.T153) is part of a Threonine-Proline motif that is 
phosphorylated during the cell cycle (Illenberger, et al., 1998) and the upstream residue (p.I151) is 
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seen to interact with microtubules using nuclear magnetic resonance (Mukrasch, et al., 2009). 
Variant p.A469T could affect the functioning of the upstream or downstream residue which might 
explain the experimental observations for this variant. This variant could elicit risk to sEOAD, 
however a large case-control association study would be needed to establish this. 
4.3. Considerations 
Although DNA microarrays are cost efficient, they have several drawbacks as evident from this 
study. The results of Sanger sequencing found that a high proportion of variants failed to verify, this 
emphasises the need to verify all genotypes called by DNA microarray technologies. The version of 
the NeuroX used in this study was only able to successfully genotype 182 of the 523 (35%) known 
causative variants documented in three online databases (Supplementary Table 3), since that time 
the number of variants documented in the online databases has increased by 147, albeit not all of 
these will be important (causative), but highlights the additional issue of having to redesign chips as 
new personal variants come to light, which questions the cost effectiveness of DNA microarray 
technology for extremely rare variants.  Next generation sequencing (NGS) technology overcomes 
the limitations and drawbacks of DNA microarray technology, and the once debilitating cost of NGS 
has almost dissipated as the price has plummeted in recent years. There is no doubt that studies like 
this should be conducted, however given the drawbacks of DNA microarray technology they would 
be better conducted using NGS technologies. 
This study has made use of an in-silico approach to classify the pathogenicity of variants; however in-
silico predictions alone are insufficient to properly appraise a variant. Richards et al have developed 
an approach that can help define the definition of ‘pathogenic’ in the clinical and research setting 
with regard to Mendelian disorders (Richards, et al., 2015), this approach makes use of additional 
types of data including population, functional and segregation data. As our understanding of 
complex diseases increases no doubt an approach incorporating several lines of data will be used to 
define pathogenic variants for non-Mendelian disorders such as sEOAD and LOAD. 
17 
 
5. Conclusion 
We have screened sporadic early-onset Alzheimer disease (sEOAD) individuals for known causative 
and predicted pathogenic variants in 16 genes linked to neurodegenerative diseases. We have 
identified nine sEOAD samples harbouring a known causative variant or a predicted pathogenic 
variant in PARK2 and MAPT. These variants could elicit risk to sEOAD in addition to PD and FTD, 
however further studies would be needed to establish this. This work highlights the need to screen 
sEOAD individuals for variants that are more classically attributed to other forms of 
neurodegeneration as there could be a degree of genetic overlap.  
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Figure Legends 
Figure 1 
Sequence chromatograms 
Sequence chromatograms of all 13 individuals thought to harbour a pathogenic (A) or predicted 
pathogenic variant (B). Each individual was sequenced in forward (top row) and reverse (bottom 
row) orientations. Note that the forward orientation does not always correspond to the sense 
strand. The images were taken from Sequence Scanner (Applied Biosystems) with the variant at the 
centre and surrounded by two or three bases either side. Four individuals (M215, M697, M172 and 
M382) show wild-type sequence according to the chromatogram.  
 
Figure 2 
SNP cluster plot for genotypes unconfirmed with Sanger sequencing 
SNP cluster graphs generated by GenomeStudio for markers NeuroX_16:31196410 (p.G225V located 
in FUS) (A), exm1331018 (p.S427F located in MAPT) (B) and exm1331027 (p.A469T located in MAPT) 
(C).  Each coloured circle represents one individual, those coloured red are homozygous mutant (TT), 
those coloured purple are heterozygous (GT), those coloured blue  are homozygous wildtype (GG), 
and finally those coloured black are not called. The plots show all ten samples called as 
heterozygotes cluster well and does not explain why four samples failed to verify with Sanger 
sequencing (M215, M697, M172 and M382). 
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Markers with updated chromosome 
List of 121 markers updated from chromosome X to the pseudo autosomal region (XY)  
 
 Supplementary Table 3 
Coverage on the NeuroX of variants from familial online databases 
Pathogenic nature and NeuroX coverage of variants from three online databases, including the Alzheimer Disease & Frontotemporal Dementia Mutation Database (AD&FTDMDB), 
Parkinson Disease Mutation Database (PDMutDB) and Human Prion Database (HPDB). Variants from the online databases were clustered into the gene they reside in (Gene) and the 
disease most associated with the gene (Disease). The number of variants in each gene is given (Database), followed by the number designed on the NeuroX (Designed on NeuroX) 
and finally the number that passed quality control in the final NeuroX dataset (Passed QC). These variants are then subcategorised depending on the pathogenicity documented in 
the database; those that cause disease (Causative), those that have unclear pathogenic nature (Pathogenic Nature Unclear), and those that do not cause disease (Not Pathogenic). 
Key: AD; Alzheimer’s disease, FTD; frontotemporal dementia, ALS; amyotrophic lateral sclerosis, PD; Parkinson’s disease. 
 
      Pathogenic Nature Unclear Causative Not Pathogenic 
Database Gene Disease Database Designed on NeuroX Passed QC Database 
Designed 
on NeuroX Passed QC Database 
Designed 
on NeuroX Passed QC Database 
Designed 
on NeuroX Passed QC 
ADFTDPD 
 
APP AD 31 10 10 6 3 3 24 6 6 1 1 1 
C9orf72 FTD/ALS 12 0 0 11 0 0 0 0 0 1 0 0 
CHMP2B FTD 12 7 7 4 0 0 4 3 3 4 4 4 
FUS FTD/ALS 44 21 20 18 3 3 22 15 15 4 3 2 
GRN FTD 146 33 33 45 10 10 66 13 13 35 10 10 
LRRK2 PD 128 71 71 54 15 15 6 3 3 68 53 53 
MAPT FTD 73 11 10 27 10 9 44 1 1 2 0 0 
PARK2 PD 144 70 70 22 4 4 59 27 27 63 39 39 
PARK7 PD 21 6 5 5 1 0 1 0 0 15 5 5 
PINK1 PD 130 52 52 30 12 12 20 7 7 80 33 33 
PSEN1 AD 197 76 74 4 3 3 185 69 67 8 4 4 
PSEN2 AD 25 9 9 5 1 1 13 5 5 7 3 3 
SNCA PD 5 1 1 1 1 1 3 0 0 1 0 0 
TARDBP FTD/ALS 45 26 26 9 3 3 34 21 21 2 2 2 
VCP FTD/ALS 20 14 14 0 0 0 18 13 13 2 1 1 
HPP PRNP Prion 42 5 5 18 4 4 24 1 1 0 0 0 
Total   1075 412 407 259 70 68 523 184 182 293 158 157 
